Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia
Lim YH, Ovejero D, Sugarman JS, DeKlotz CM, Maruri A, Eichenfield LF, Kelley PK, Jüppner H, Gottschalk M, Tifft CJ, Gafni RI, Boyce AM, Cowen EW, Bhattacharyya N, Guthrie LC, Gahl WA, Golas G, Loring EC, Overton JD, Mane SM, Lifton RP, Levy ML, Collins MT, Choate KA. Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Human Molecular Genetics 2013, 23: 397-407. PMID: 24006476, PMCID: PMC3869357, DOI: 10.1093/hmg/ddt429.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildExomeFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsGene Expression Regulation, DevelopmentalGTP PhosphohydrolasesHumansHypophosphatemiaMaleMembrane ProteinsMutationNevusNevus, PigmentedOsteomalaciaProto-Oncogene Proteins p21(ras)Sequence Analysis, DNASkinSkin NeoplasmsConceptsSerum FGF23 levelsElevated serum FGF23Congenital melanocytic neviSomatic activating mutationsFGF23 levelsSerum FGF23Bone lesionsMelanocytic neviActivating mutationsElevated serum FGF23 levelsFibroblast growth factor 23Giant congenital melanocytic nevusElevated serum levelsGrowth factor 23Regulation of FGF23Bone-derived hormoneRenal phosphate wastingLarge congenital melanocytic neviDysplastic boneElevated FGF23Factor 23Serum levelsCutaneous disordersPhosphate wastingInvolved tissues